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We have reported evidence for a positive regulatory circuit between interferon regulatory factor 7 (IRF7) and
the Epstein-Barr virus (EBV) oncoprotein 1 (LMP1) (S. Ning, A. M. Hahn, and J. S. Pagano, J. Virol.
77:9359–9368, 2003). To explore a possible braking mechanism for this circuit, several type II EBV-infected cell
lines that express different levels of LMP1 and IRF7 proteins and therefore are convenient for studying
modulation of expression of LMP1 were analyzed. Endogenous levels of IRF7 and LMP1 were directly
correlated. Transient expression of an IRF7 dominant-negative mutant decreased LMP1 levels. Endogenous
IRF5 and IRF7 proteins were shown to physically associate in EBV-positive cells. Transient expression of IRF5
decreased activation of the LMP1 promoter by IRF7 in a dose-dependent manner. Finally, transfection of
either an IRF5 dominant-negative construct or IRF5 small interfering RNA in these cells resulted in increases
in endogenous levels of LMP1. These results indicate that IRF5 can downregulate IRF7’s induction of
expression of LMP1 most likely by interacting with IRF7 and provide a means of modulating a regulatory
circuit between IRF7 and LMP1.
The interferon (IFN) regulatory factor (IRF) family, which
consists of 10 members, plays essential roles in the activation of
innate immune response to viral infection (reviewed in refer-
ences 3, 7, 11, 12, and 24). IRF3 and IRF7, two of the family
members, are indispensable for induction of alpha/beta IFNs
(IFN-/) upon virus infection (reviewed in references 3, 7, 12,
and 24) through Toll-like receptor (TLR) signaling (6, 8, 13,
14, 17, 24, 30, 33, 42). IRF7 is now considered the master
regulator of IFN-/-dependent immune responses (15).
IRF5, characterized more recently, also participates in induc-
tion of IFN-/ upon virus infection (4) through TLR signaling
(32, 37). Thus, three members of the IRF family, IRF3, IRF7,
and IRF5, are directly involved in signaling pathways triggered
by virus infection (reviewed in references 3 and 24).
As the versatile principal oncoprotein of the human gamma
herpesvirus Epstein-Barr virus (EBV), latent membrane pro-
tein 1 (LMP1) has been extensively studied and is remarkable
for its ability to activate at least seven signaling pathways,
including the NF-B, p38/MAPK, Jak/STAT, JNK/AP-1, and
PI3K/Akt pathways, via its C-terminal activation domains. The
other two pathways, ubiquitination and CDC42 activation, are
mediated by LMP1 N-terminal and transmembrane domains,
respectively (reviewed in references 9 and 20). Induction of
expression of LMP1 depends on several virus-specific factors,
the best characterized of which is the transcriptional activator
EBV nuclear antigen 2 (EBNA2) (16, 34, 35, 38, 40).
Our previous work uncovered the intimate involvement of
IRF7 in EBV latency and showed first that IRF7, along with
IRF2, represses the promoter used for expression of EBNA1
in type I latency in which latent gene expression is most re-
stricted (45). We then detailed a special relationship between
IRF7 and LMP1, which is capable of both inducing expression
of and activating IRF7 (46, 49). Subsequently, we showed that
there is also a reciprocal action of IRF7 on expression of
LMP1 in that the cellular protein can activate the LMP1 pro-
moter and induce expression of the viral protein (28). Most
recently, we have demonstrated that expression of IRF7 is
itself upregulated by IRF7 in an IFN-independent manner
(29). Thus, expression of LMP1 and that of IRF7 are closely
linked, which opens the possibility of functional consequences.
This linkage is reflected biologically in functional interac-
tions of the viral and cellular proteins. Besides the established
oncogenicity of LMP1, IRF7 itself has oncogenic properties,
which enhance LMP1’s oncogenicity in cell-culture assays and
tumor formation in animal models (50). The most interesting
verification of a possible physiological interaction of these two
proteins comes from discovery of overexpression and activa-
tion of IRF7 in EBV-positive central nervous system lympho-
mas (50). Thus, not only does IRF7 induce LMP1, but it also
appears to potentiate its oncogenic effects. Consequently, how
modulation of the regulatory circuitry of these two proteins is
brought about becomes an important question. Specifically, if
IRF7 functions to upregulate LMP1, is there a mechanism for
dampening or braking such an effect?
It has been reported that IRF5/IRF3 heterodimers and
IRF5/IRF5 homodimers can activate IFN- gene (IFNA) tran-
scription, since in virus-infected cells transfected with IRF5 the
levels of IFNA transcripts are higher in the presence than in
the absence of IRF3. In the absence of both IRF3 and IRF7,
IRF5 alone is able to bind to the virus-responsive element of
IFNA genes and induce low levels of IFN- in virus-infected
cells (4). However, IRF5 also forms heterodimers with IRF7,
and IRF5/IRF7 complexes repress IFNA transcription in virus-
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infected cells, since IFNA transcription could not be activated
in cells cotransfected with IRF5 and IRF7, whereas it could be
activated in cells transfected with either IRF5 or IRF7 alone
(1). Thus, IRF5/IRF3 heterodimers and IRF5/IRF5 ho-
modimers activate but IRF5/IRF7 heterodimers repress tran-
scription of the same set of genes.
In this study, we show that endogenous IRF5 and IRF7 can
physically associate and that IRF5/IRF7 heterodimers inhibit
the induction by IRF7 of expression of LMP1 in EBV-infected
cells. Reduction of endogenous levels or activity of IRF5 pro-
duces increased levels of LMP1.
MATERIALS AND METHODS
Cell lines. The EBV-infected human breast cancer cell line MDA-MB-231
clones C4A3, C1D12, C2G6, and C3B4 were generous gifts from Irene Joab
(INSERM EPI 03–34, IUH, Hospital Saint-Louis, Paris, France) and were main-
tained in RPMI 1640 medium supplied with 2 mM L-glutamine, 700 g/ml G-418
(GIBCO), 10% fetal bovine serum (FBS), and penicillin-streptomycin.
BJAB is an EBV-negative human Burkitt’s lymphoma (BL) cell line. JiJoye is
a type III EBV-positive human BL cell line. P3HR-1, a mutant cell line derived
from JiJoye, has a deletion of portions of the EBNA-LP and EBNA2 open
reading frames and expresses low levels of LMP1. All the cell lines were grown
in RPMI 1640 medium supplemented with 10% FBS and penicillin-streptomycin.
The 293 cell line, derived from human kidney epithelial cells, was grown in
Dulbecco’s modified Eagle medium with 10% FBS and penicillin-streptomycin.
Plasmids and antibodies. pcDNA3-IRF7A (45), pCMVsport-IRF5 (4), and
Flag-IRF5 (4) were described previously. Flag-IRF5DN was constructed by in-
serting IRF5DN (deletion of DNA-binding domain, amino acids 35 to 136) into
pCMV2-Flag vector. pGL2(512/72)LMP1p-Luc has two directly repeated
copies of the LMP1 512/72 promoter element and was a gift from Jeffery Lin
and Elliott Kieff (21). The pGL3/IFN-p-Luc construct was described previously
(22).
IRF7 rabbit polyclonal antibody (H-246) was purchased from Santa Cruz,
IRF5 goat polyclonal antibody (ab2932) was purchased from Abcam, EBNA2
(PE2) and LMP1 (CS1-4) monoclonal antibodies were from Dako, and -tubulin
monoclonal antibody was from Sigma.
IRF5 RNA interference (RNAi) assay. Cells in 60-mm dishes were transfected
with 60 nmol IRF5 small interfering RNA (siRNA; Ambion) or negative control
siRNA (Ambion) with the use of TransPass R1 transfection reagent (New En-
gland BioLabs Inc.) following the manufacturer’s instructions. The negative
control siRNAs are comprised of a 19-bp scrambled sequence with 3 dT over-
hands; the sequences have no significant homology to any known gene sequences
from mice, rats, or humans. The IRF5 siRNA targets both transcript variants of
human IRF5, NM_002200 exon 2 and NM_032643 exon 3. The medium was
replaced 12 h after transfection. Cells were collected for Western blot analyses
after 60 h.
Transfection and reporter assays. 293 cells in 12-well plates were transfected
with an Effectene kit following the manufacturer’s instructions (QIAGEN). For
12-well plates, 0.4 g total plasmids was transfected. Vector DNA was added to
equalize the total amount of DNA used in all transfections. Cells were collected
48 h after transfection. For luciferase assays, the transfected cells were collected
48 h posttransfection. Cell lysates (20 l each) were combined with luciferase
assay reagent (Promega), and the relative light units were measured in an Lmax
luminometer (Molecular Devices Corp.). The transfection efficiencies were nor-
malized to -galactosidase values. Reporter assay results presented are from
single experiments representative of multiple independent trials.
P3HR1 cells were transfected with 5 g plasmids with an electroporator at 210
V and 975 F. After electroporation, cells were resuspended in 10 ml complete
medium and incubated for 48 h.
Immunoprecipitation. Cells were lysed in radioimmunoprecipitation assay
(RIPA) lysis buffer (150 mM NaCl, 1% NP-40, 0.5% Na deoxycholate, and 0.1%
sodium dodecyl sulfate [SDS]). Proteins (200 g) in cell lysates were applied for
each immunoprecipitation. Cell lysates (500 l) were precleared with 1 g of
appropriate immunoglobulin G (IgG) plus 50 l of protein A/G beads (Santa
Cruz) for 1 h. After preclearing, cell lysates were incubated with 1 g of antibody
or IgG for 4 h. Beads were extensively washed with RIPA buffer and resuspended
in an equal volume of 2	 SDS loading buffer and RIPA buffer.
Western blotting. Cells were lysed in RIPA lysis buffer as above. Cells lysates
(100 g of total proteins each lane) were separated on 10% SDS-polyacrylamide
gel electrophoresis gels for detection of IRF7, IRF5, and LMP1. The proteins
were then transferred to nitrocellulose membranes. Membranes were blocked in
5% milk before incubation with specific antibodies for 2 h at room temperature.
The specific primary antibodies were applied at dilutions of 1:500 for IRF7 and
IRF5, 1:300 for LMP1, and 1:10,000 for -tubulin. Appropriate horseradish
peroxidase-conjugated secondary antibodies were applied at a dilution of 1:3,000
for 1 h at room temperature. Specific signals were detected by enhanced chemi-
luminescence following the manufacturer’s protocol (Amersham Pharmacia Bio-
tech).
RESULTS
IRF7 and LMP1 levels directly correlate in type II EBV-
positive cells. In a previous study we showed that when IRF7
is introduced into P3HR1 cells, which have low levels of IRF7
and lack EBNA2, it can induce LMP1 expression indepen-
dently of EBNA2. This finding offered an explanation for how
LMP1 might be expressed in type II cells where EBNA2 pro-
tein is absent (28). To test this idea further, but directly in type
II cells, we examined endogenous IRF7 and LMP1 levels in a
series of cell lines, the C1D12, C2G6, C3B4, and C4A3 clones,
all of which are EBV-infected cells with the type II phenotype
derived from the human breast cancer cell line MDA-MB-231.
These clones express different levels of LMP1 and do not
express EBNA2. Western blotting results show consistent cor-
relation of IRF7 and LMP1 levels in these clones (Fig. 1A).
C3B4 cells have the highest level of both LMP1 and IRF7,
whereas in C4A3 cells LMP1 is not detectable and the IRF7
level is low. These results are consistent with findings in a
previous study (39). Further, we transfected the clone with the
highest level of IRF7, C3B4, with an IRF7 dominant-negative
construct and showed that reduction in IRF7 activity decreased
FIG. 1. Correlation of IRF7 with LMP1 protein levels in type II
EBV-positive cells. (A) Cell lysates prepared from C1D12, C2G6,
C3B4, and C4A3 were subjected to Western blot analysis with specific
antibodies to LMP1 and IRF7. For each lane, 150 g of total protein
was loaded. (B) C3B4 cells, which express the highest levels of LMP1,
were transfected with Flag-IRF7DN or empty vector pCMV2-Flag.
After 48 h, cell lysates were prepared and Western blotting was per-
formed with LMP1 and IRF7 antibodies.
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the level of LMP1 (Fig. 1B). Thus, the LMP1 expressed in
these type II cells appears to depend on expression of IRF7.
IRF5 interacts with IRF7 in EBV-positive cells. Expression
of IRF7 induces the LMP1 promoter and increases levels of
LMP1 RNA and proteins (28). To explore whether IRF5 can
interact with IRF7 and affect its ability to induce expression of
LMP1, first we checked the endogenous IRF7 and IRF5 levels
in a variety of cell lines, including EBV-negative BJAB cells
and type II and type III cells. As shown in Fig. 2A, in all the cell
lines tested both IRF7 and IRF5 were detected. Levels of IRF7
were lower in the breast cancer cells, which is expected because
IRF7 is preferentially expressed in cells of lymphoid origin
(45). Human IRF5 protein has two isoforms resulting from two
transcripts of 2.4 and 3.4 kilobases (4), and the IRF5 antibody
used in this study recognizes both isoforms. Next, we per-
formed immunoprecipitation assays in three representative
EBV-positive cell lines, including the type II C3B4 cells and
type III P3HR1 and JiJoye cells. In the cell lysates immuno-
precipitated with IRF7 antibody, IRF5 was detected in all
cases (Fig. 2B, upper panel). In the converse experiment, in
immunoprecipitates of the cell lysates incubated with IRF5
antibody, IRF7 was detected in all three cell lines (Fig. 2B,
lower panel). Thus, the results show that endogenous IRF5
physically interacts with IRF7 in EBV-infected cells.
Transient expression of IRF5 reduces LMP1 promoter ac-
tivity induced by IRF7. To test whether IRF5 might affect the
function of IRF7 we studied its effect on induction of the
LMP1 promoter by IRF7. 293 cells were cotransfected with an
LMP1 promoter-luciferase reporter construct, pLMP1p-Luc, a
constant amount of an IRF7 expression construct, pcDNA3-
IRF7, and increasing amounts of an IRF5 expression con-
struct, pcDNA3-IRF5. As expected, IRF7 alone activated
pLMP1p-Luc 10-fold. IRF5 alone had little if any effect on the
LMP1 promoter. However, expression of increasing amounts
of IRF5 progressively decreased LMP1 promoter activity in-
duced by IRF7 in a dose-dependent manner (Fig. 3). Thus,
expression of IRF5 could override the transactivation function
of IRF7.
Inhibition of IRF5 function or repression of IRF5 expres-
sion elevates LMP1 levels in type II EBV-positive cells. Since
the C1D12 and C2G6 clones express very low levels of LMP1,
we used these two cell lines in IRF5 dominant-negative and
RNAi assays to check if endogenous LMP1 levels can increase
after inhibition of IRF5 function or repression of its expres-
sion. First, we transfected these two lines and the B-cell line
P3HR1 with an IRF5 dominant-negative construct and deter-
mined changes in LMP1 levels. As shown in Fig. 4A, expres-
sion of IRF5DN consistently increased LMP1 protein levels.
Interestingly, in P3HR1 cells, where there was no detectable
LMP1, a low level of LMP1 could be detected after expression
of IRF5DN. No differences in IRF7 levels were detected in
cells transfected with empty vector and IRF5DN (Fig. 4A).
Thus, the increases in endogenous levels of LMP1 resulted
from decreased levels or function of IRF5, not from changes in
IRF7 levels. Inhibition of IRF5 function by IRF5DN is tested
(Fig. 4B).
Next, we used RNAi to IRF5 to reduce its expression levels
in type II cells. IRF5 siRNA (siIRF5) and scrambled negative-
control siRNA oligomers were transfected into C1D12 and
C2G6 cells. Western blot analyses for LMP1, IRF5, and IRF7
were performed after 60 h. As shown in Fig. 4C, in cells
transfected with negative-control siRNA, levels of LMP1 were
the same as in mock-transfected cells. However, there were
significant elevations of LMP1 protein levels detected in cells
FIG. 2. Association of IRF7 with IRF5 in EBV-positive cells.
(A) Detection of endogenous IRF5 in different cell lines. For each
lane, 100 g of total protein was loaded. (B) IRF5 is associated with
IRF7 in EBV-positive cells. Total protein (200 g) in cell lysates was
precleared with normal IgG and divided into equal amounts. One was
subjected to immunoprecipitation (IP) with specific antibodies against
IRF5 or IRF7, and the other with normal IgG. After extensive wash-
ing, immunoprecipitates were analyzed by Western blotting with IRF5
or IRF7 antibodies. IB, immunoblot.
FIG. 3. IRF5 represses IRF7 activation of the LMP1 promoter. 293
cells in 12-well plates were cotransfected with pLMP1p-Luc, IRF7, and
increasing amounts of IRF5 expression plasmid. -Galactosidase ex-
pression plasmid was cotransfected as an internal control. Equal
amounts of cell lysates were assayed for luciferase activity 48 h after
transfection. Activation is shown relative (n-fold) to the basal level of
the reporter gene response to empty vector.
VOL. 79, 2005 IRF5 DOWNREGULATES IRF7 INDUCTION OF EBV LMP1 11673
transfected with siIRF5, and, correspondingly, the levels of IRF5
protein were obviously decreased, but IRF7 levels were again
unchanged (Fig. 4C). The IRF5 RNAi results indicate that re-
pression of IRF5 expression could increase endogenous LMP1
levels in type II cells. These results are consistent with the idea
that an upregulatory circuit between IRF7 and LMP1 can be
retarded by IRF5.
DISCUSSION
A function for IRF5 was revealed only recently when it was
shown to induce expression of distinct IFNA gene subtypes
upon Newcastle disease virus, vesicular stomatitis virus, and
herpes simplex virus type 1 infection (2, 4). Appreciated more
recently is the ability of IRF5, as well as IRF7, to stimulate a
broad profile of host genes encoding other proteins in addition
to antiviral proteins (5). In contrast to its ability to activate
IFNA promoters (4), which is shared by IRF7 (reviewed in
references 7, 19, and 47), IRF5 has no detectable effect on the
LMP1 promoter (Fig. 3), whereas IRF7 can induce expression
of LMP1 as shown previously (28) and confirmed here, al-
though it has a lesser effect than EBNA2 (Fig. 5, pathway 1).
Instead, IRF5 inhibits expression of LMP1 in type II cells,
most likely by interacting with IRF7. These findings implicate
IRF5 in the modulation of stimulatory effects produced by
IRF7 on expression of LMP1. This modulatory mechanism,
which uses different signaling pathways from EBNA2, the
prime enhancer used for LMP1 expression in type III cells (16,
34, 35, 38, 40, 44a), becomes evident only in the absence of
expression of EBNA2, the more potent activator.
Regulation of LMP1 transcription is critical because it is
FIG. 4. Repression of IRF5 function increases LMP1 protein levels in type II cells. (A) Overexpression of an IRF5 dominant-negative mutant
elevates LMP1 levels in type II C1D12 and C2G6 cells and in type III P3HR1 cells. C1D12 and C2G6 cells in 60-mm dishes were transfected with
2 g pCMV2-Flag empty vector or pCMV2-Flag/IRF5DN with the use of an Effectene kit. P3HR1 cells were transfected with 5 g of plasmids
by electroporation, as described in Materials and Methods. Cells were collected 48 h after transfection, and cell lysates were used for Western blot
analyses with specific antibodies against LMP1 and IRF7. (B) Inhibition of IRF5 function by the tested IRF5DN. A pGL3/IFN-p-Luc construct
was used. A promoter-reporter assay was performed as above. (C) Silencing of expression of endogenous IRF5 by siIRF5 elevates LMP1 levels.
C1D12 and C2G6 cells in 60-mm dishes were transfected with 60 nmol siIRF5 or negative control siRNA. Medium was changed after 12 h. Cells
were collected 60 h after transfection, and lysates were used for Western blot analyses with specific antibodies against LMP1, IRF5, and IRF7.
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essential for EBV’s hallmark function, growth transformation
of B lymphocytes (21, 35, 36). The finding that IRF7 induces
expression of LMP1 provides a possible partial explanation for
how LMP1 is expressed, although at low levels, in type II cells
in the absence of EBNA2 (28) (Fig. 5, pathway 1). We have
also shown that LMP1 can induce expression of IRF7 in ad-
dition to promote IRF7 phosphorylation (46) (Fig. 5, pathways
2 and 3), which may help to explain why IRF7 is expressed at
appreciable levels in type II nasopharyngeal carcinoma tissues
(L. Zhang and J. Pagano, unpublished results). The present
results confirm that there is a positive regulatory circuit be-
tween IRF7 and LMP1, which as previously reported potenti-
ates both expression and oncogenic properties of the two genes
(28, 50). Recently, we also demonstrated that IRF7 can be
autoregulated by binding IRF7-containing virus-activated fac-
tor to the IRF7 promoter (29), thereby promoting the circuit
(Fig. 5, pathway 4). The main results in this paper now show
that endogenous IRF5 and IRF7 can associate in EBV-in-
fected cells and suggest that IRF5/IRF7 heterodimers nega-
tively regulate this circuit (Fig. 5, pathway 5) so that a possible
“runaway” effect on expression of the toxic LMP1 oncoprotein
(10, 27) is modulated. Also, our findings add new elements as
to how type II latency is maintained.
Certain members of the IRF family have an IRF association
domain, which confers on each of them the ability to associate
with itself or another IRF member in activating their target
genes (25). For example, IRF8 interacts with IRF1 or IRF2
(reviewed in reference 18), and IRF3 and IRF7 can form
IRF3/IRF3 and IRF7/IRF7 homodimers and IRF3/IRF7 het-
erodimers in induction of IFN-/ (22, 29, 41, 43, 44). As to
IRF5, it can form IRF5/IRF5 homodimers and IRF5/IRF7 and
IRF5/IRF3 heterodimers. IRF5/IRF3 and IRF5/IRF5 can ac-
tivate IFNA gene transcription, whereas IRF5/IRF7 inhibits it
(1, 2, 4). Thus, IRF5 may function either to inhibit or to
stimulate expression of IFNA genes, depending on its binding
partners. This inhibition results from masking of the IRF5 and
IRF7 DNA-binding domains after heterodimer formation (1).
Definitely, masking of the IRF5 and IRF7 DNA-binding do-
mains abolishes the ability of these proteins to bind to all their
targets, including LMP1. Thus, masking also provides an ex-
planation for the inhibition of induction of LMP1 by IRF5/
IRF7 interaction as shown in this study, and it is likely that the
effect of IRF5 on IRF7 is not restricted to IFNA and LMP1
genes. We hypothesize that the balance between supply of
IRF5 and IRF7 protein molecules may determine if the posi-
tive circuit between IRF7 and LMP1 becomes negatively reg-
ulated.
Perhaps the most striking findings in this study are provided
by the effects of the IRF5 dominant-negative construct and by
IRF5 RNAi in EBV-infected cells. Both repression of the
function of IRF5 and reduction of levels of this protein pro-
duced increases in levels of endogenous LMP1 protein (Fig. 4).
In these different cell lines, since the endogenous levels of
IRF7 were unchanged in all cases, these results suggest a direct
mechanism for modulation of LMP1 levels in type II cells.
Although we only show evidence of negative modulation of
LMP1 by IRF5, we believe that other IRF family members may
be involved in regulation of this circuit by induction or inhibi-
tion of expression of IRF7 and LMP1. IRF1, which can bind to
the IRF7 promoter, is suggested to activate the IRF7 promoter
in IFN-treated cells (23), and IRF9 can induce IRF7 upon
virus infection and IFN treatment (23, 26, 31). In fact, IRF2,
which usually functions as a transcriptional repressor, is also
capable of binding to the IRF7 promoter strongly, whereas
IRF5 has a very weak ability to bind to the IRF7 promoter, as
shown by in vitro binding assays (data not shown). Thus, a
complex rigorously regulatory network that controls expression
of LMP1, governed by interplay between viral and cellular
factors, is emerging. These interactions, exemplified by the
type II latent infection state, are likely to have significance for
EBV latency, oncogenesis, and evasion of host defense re-
sponses.
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